94,586 Shares in Sanofi (NASDAQ:SNY) Acquired by International Assets Investment Management LLC

International Assets Investment Management LLC bought a new position in Sanofi (NASDAQ:SNY) in the fourth quarter, according to the company in its most recent 13F filing with the SEC. The fund bought 94,586 shares of the company’s stock, valued at approximately $4,704,000.

Other hedge funds also recently bought and sold shares of the company. Sage Rhino Capital LLC lifted its position in Sanofi by 2.8% in the third quarter. Sage Rhino Capital LLC now owns 8,722 shares of the company’s stock valued at $468,000 after purchasing an additional 240 shares during the last quarter. Gallacher Capital Management LLC lifted its position in Sanofi by 4.5% in the third quarter. Gallacher Capital Management LLC now owns 5,715 shares of the company’s stock valued at $307,000 after purchasing an additional 245 shares during the last quarter. Captrust Financial Advisors lifted its position in Sanofi by 0.9% in the third quarter. Captrust Financial Advisors now owns 26,191 shares of the company’s stock valued at $996,000 after purchasing an additional 246 shares during the last quarter. Rise Advisors LLC lifted its position in Sanofi by 98.4% in the fourth quarter. Rise Advisors LLC now owns 506 shares of the company’s stock valued at $25,000 after purchasing an additional 251 shares during the last quarter. Finally, Pathstone Family Office LLC lifted its position in Sanofi by 1.7% in the fourth quarter. Pathstone Family Office LLC now owns 14,962 shares of the company’s stock valued at $705,000 after purchasing an additional 251 shares during the last quarter. Institutional investors own 10.04% of the company’s stock.

Analyst Upgrades and Downgrades

A number of equities analysts recently commented on SNY shares. Morgan Stanley started coverage on Sanofi in a report on Tuesday, January 23rd. They set an “equal weight” rating and a $55.00 target price for the company. StockNews.com downgraded Sanofi from a “strong-buy” rating to a “buy” rating in a report on Tuesday, February 27th. Finally, TheStreet downgraded Sanofi from a “b” rating to a “c” rating in a report on Friday, February 9th. One investment analyst has rated the stock with a sell rating, three have issued a hold rating and three have given a buy rating to the stock. According to data from MarketBeat, the stock presently has an average rating of “Hold” and an average price target of $55.00.

Sanofi Price Performance

Shares of SNY stock opened at $45.80 on Wednesday. The stock has a market cap of $115.86 billion, a price-to-earnings ratio of 19.41, a PEG ratio of 1.72 and a beta of 0.61. The business’s fifty day moving average is $47.56 and its 200 day moving average is $48.71. Sanofi has a twelve month low of $42.63 and a twelve month high of $57.82. The company has a quick ratio of 0.87, a current ratio of 1.27 and a debt-to-equity ratio of 0.19.

Sanofi (NASDAQ:SNY) last issued its quarterly earnings results on Thursday, February 1st. The company reported $0.89 earnings per share for the quarter, missing the consensus estimate of $0.94 by ($0.05). The firm had revenue of $11.76 billion during the quarter, compared to analysts’ expectations of $13.02 billion. Sanofi had a return on equity of 27.47% and a net margin of 12.56%. Research analysts expect that Sanofi will post 4.16 EPS for the current fiscal year.

Sanofi Increases Dividend

The company also recently declared an annual dividend, which will be paid on Thursday, June 6th. Investors of record on Friday, May 10th will be paid a $1.478 dividend. This represents a yield of 2.98%. This is a boost from Sanofi’s previous annual dividend of $1.38. The ex-dividend date of this dividend is Thursday, May 9th. Sanofi’s dividend payout ratio is presently 58.47%.

Sanofi Company Profile

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.